Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RDHL 
Redhill Biopharma Ltd (RDHL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: RDHL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $19000
1 Year Target Price $19000
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.93% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.03M USD | Price to earnings Ratio - | 1Y Target Price 19000 |
Price to earnings Ratio - | 1Y Target Price 19000 | ||
Volume (30-day avg) 1 | Beta 4.22 | 52 Weeks Range 1.71 - 20.27 | Updated Date 07/12/2025 |
52 Weeks Range 1.71 - 20.27 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -102.8% | Operating Margin (TTM) -69.57% |
Management Effectiveness
Return on Assets (TTM) -37.28% | Return on Equity (TTM) -1708.61% |
Valuation
Trailing PE - | Forward PE 1428.57 | Enterprise Value 765805 | Price to Sales(TTM) 0.62 |
Enterprise Value 765805 | Price to Sales(TTM) 0.62 | ||
Enterprise Value to Revenue 0.1 | Enterprise Value to EBITDA 0.3 | Shares Outstanding 2295340 | Shares Floating 11469754846 |
Shares Outstanding 2295340 | Shares Floating 11469754846 | ||
Percent Insiders - | Percent Institutions 5.67 |
Upturn AI SWOT
Redhill Biopharma Ltd
Company Overview
History and Background
Redhill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. Founded in 2009, it develops and commercializes pharmaceutical products.
Core Business Areas
- Gastrointestinal Diseases: Focuses on developing and commercializing therapies for gastrointestinal diseases, including inflammatory bowel disease (IBD) and other GI conditions.
- Infectious Diseases: Developing therapies for infectious diseases, including COVID-19 and H. pylori infections.
Leadership and Structure
Gilead Raday (CEO), Micha Ben Chorin (CFO). The company structure includes research and development, commercial operations, and regulatory affairs departments.
Top Products and Market Share
Key Offerings
- Talicia: A combination of omeprazole, amoxicillin and rifabutin used to treat Helicobacter pylori (H. pylori) infection. Competing products include triple therapy regimens. It generated approximately $6.1 million USD in net revenue for the first nine months of 2023. Competitors include standard triple therapy, clarithromycin-based therapies, and bismuth-based therapies.
- Movantik: Treats opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Marketed in the US by a partner. Competitors include Relistor, Amitiza, and Symproic.
- Opaganib: An investigational oral pill for COVID-19. Awaiting further trials. Competitors include Paxlovid and Molnupiravir.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and strong competition. Increased focus on personalized medicine and innovative therapies.
Positioning
Redhill Biopharma is a specialty pharma company, focusing on niche markets with specific unmet needs. Their advantage lies in their targeted product portfolio.
Total Addressable Market (TAM)
The TAM varies depending on the specific indication and product. The gastrointestinal disease market is estimated to be in the billions of dollars. Redhill aims to capture specific segments through targeted therapies.
Upturn SWOT Analysis
Strengths
- Specialty focus on gastrointestinal and infectious diseases
- Established commercial infrastructure
- Proprietary drug candidates
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on key products
- Regulatory risks
- Intense competition in the pharmaceutical industry
Opportunities
- Expanding product pipeline through acquisitions or licensing
- Entering new markets
- Securing partnerships with larger pharmaceutical companies
- Gaining regulatory approvals for new products
Threats
- Competition from larger pharmaceutical companies
- Generic erosion of key products
- Failure to obtain regulatory approvals
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- AGN
- ABBV
- PFE
- MRK
Competitive Landscape
Redhill is a smaller player in a competitive pharmaceutical market. Its strengths lie in its specialized focus and targeted therapies.
Major Acquisitions
Esomeprazole Strontium Delayed-Release Capsules 49.3 mg
- Year: 2020
- Acquisition Price (USD millions): 4.5
- Strategic Rationale: Added a proton pump inhibitor to the portfolio.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the commercialization of Talicia and other products, but subject to market volatility.
Future Projections: Future growth depends on the success of ongoing clinical trials, regulatory approvals, and commercial partnerships. Analyst projections are speculative.
Recent Initiatives: Focus on strategic acquisitions, pipeline expansion, and commercial partnerships.
Summary
Redhill Biopharma is a specialty biopharmaceutical company with a focus on gastrointestinal and infectious diseases. While they have approved products and a commercial infrastructure, their financial resources are limited, and the market is intensely competitive. Success hinges on clinical trial outcomes and securing strategic partnerships. The company faces threats from larger competitors and regulatory risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, SEC filings, Analyst reports, Redhill Biopharma website
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Redhill Biopharma Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2013-01-07 | Co-Founder, Chairman & CEO Mr. Dror Ben-Asher | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 35 | Website https://www.redhillbio.com |
Full time employees 35 | Website https://www.redhillbio.com | ||
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.